Pfizer's Anacor deal showcases new wave of eczema therapies
Steroid-free topical ointment and injectable therapy reduce symptoms in late-stage trials without side effects
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
PFIZER Inc's purchase of Anacor Pharmaceuticals Inc heralds an approaching wave of potentially safer and more effective treatments for millions who suffer from eczema, a common skin condition which causes infection-prone rashes that can feel like having poison ivy 24 hours a day.
More than two dozen drugmakers are working on novel medicines to treat the condition - also known as atopic dermatitis - affecting about 20 million Americans, and Pfizer's US$5.2 billion deal positions it to become a market leader.
Anacor's steroid-free topical ointment crisaborole is the first of the new treatments to be reviewed by US regulators. An injectable therapy called dupilumab from Regeneron Pharmaceuticals Inc is expected to be submitted for US approval later this year.
Share with us your feedback on BT's products and services
